Genmab A/S (GMAB)
NASDAQ·Healthcare·Biotechnology
$26.78
+0.53%
Mkt Cap $16.79B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 17, 2026 | $1.07B | $1.06B | -0.76% | $0.46 | $0.05 | -89.13% | — | — |
| Q4 2025 Nov 6, 2025 | $1.01B | $1.02B | +1.08% | $0.48 | $0.65 | +35.42% | — | — |
| Q3 2025 Aug 7, 2025 | $952.56M | $924.81M | -2.91% | $0.39 | $0.54 | +38.46% | — | — |
| Q2 2025 May 8, 2025 | $755.47M | $725.99M | -3.90% | $0.23 | $0.31 | +34.78% | — | — |
| Q1 2025 Feb 12, 2025 | $791.87M | $891.43M | +12.57% | $0.28 | $0.57 | +103.57% | — | — |
| Q4 2024 Nov 6, 2024 | $809.62M | $815.16M | +0.68% | $0.35 | $0.29 | -17.14% | — | — |
| Q3 2024 Aug 8, 2024 | $679.43M | $777.83M | +14.48% | $0.29 | $0.22 | -24.14% | — | — |
| Q2 2024 May 2, 2024 | $530.81M | $594.93M | +12.08% | $0.16 | $0.16 | +0.00% | — | — |
| Q1 2024 Feb 14, 2024 | $671.21M | $690.33M | +2.85% | $0.34 | $0.36 | +5.88% | — | — |
| Q4 2023 Nov 7, 2023 | $642.86M | $669.38M | +4.13% | $3.14 | $0.47 | -85.03% | — | — |
| Q3 2023 Aug 3, 2023 | $601.13M | $613.29M | +2.02% | $2.18 | $0.30 | -86.24% | — | — |
| Q2 2023 May 10, 2023 | $404.26M | $416.08M | +2.92% | $0.65 | $0.05 | -92.31% | — | — |
| Q1 2023 Feb 22, 2023 | $681.42M | $754.97M | +10.79% | $3.15 | $0.12 | -96.19% | — | — |
| Q4 2022 Nov 9, 2022 | $473.49M | $535.64M | +13.13% | $1.65 | $0.53 | -67.88% | — | — |
| Q3 2022 Aug 10, 2022 | $412.04M | $443.98M | +7.75% | $1.55 | $0.41 | -73.55% | — | — |
| Q2 2022 May 11, 2022 | $300.49M | $315.14M | +4.88% | $0.91 | $0.11 | -87.91% | — | — |
| Q1 2022 Feb 16, 2022 | $389.00M | $399.16M | +2.61% | $5.30 | $0.17 | -96.79% | — | — |
| Q4 2021 Nov 10, 2021 | $270.35M | $360.41M | +33.31% | $0.11 | $0.21 | +90.91% | — | — |
| Q3 2021 Aug 11, 2021 | $353.27M | $314.36M | -11.02% | $0.08 | $0.08 | +0.00% | — | — |
| Q2 2021 May 5, 2021 | $214.32M | $249.78M | +16.54% | $0.23 | $0.27 | +17.39% | — | — |